Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer

Anti-Cancer Drugs

Volumn 13, Issue 8, 2002, Pages 791-795

  Paciucci, Paolo Alberto ^a   Raptis, George ^a   Bleiweiss, Ira ^a   Weltz, Christina ^a   Lehrer, Deborah ^a   Gurry, Rita ^a  

^a MOUNT SINAI HOSPITAL   (United States)

Author keywords

Breast cancer; Docetaxel; Neo adjuvant chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; DYSPNEA; EDEMA; EYE DISEASE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; ONYCHOLYSIS; PAIN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FILGRASTIM; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; TAXOIDS;

EID: 0036746903     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200209000-00002     Document Type: Article

References (22)

1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85
2. van Der Hage JA, van De Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001; 19: 4224-37
3. Eltahir A, Heys SD, Hutcheon AW, et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 1998; 175: 127-32
4. Nabholtz JM, Crown J. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results. Semin Oncol 1998; 25: 4-9
5. Crown J. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer. Semin Oncol 1999; 26: 5-9
6. Aapro M. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group. Semin Oncol 1998; 25: 7-11
7. Nabholtz JM, Smylie M, Mackey JR, et al. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer. Oncology (Huntingt) 1997; 11: 37-41
8. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17: 2341-54
9. Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999; 10: 553-60
10. Muthalib A, Darwis I, Prayogo N, Sutjipto S. Preliminary results of multicenter phase II trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer. Gan To Kagaku Ryoho 2000; 27(suppl 2): 498-504
11. Alexopoulos A, Kouroussis C, Malamos N, et al. Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. Ann Oncol 2001; 12: 793-8
12. Ibrahim NK, Rahman Z, Valero V, et al. Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. Cancer Invest 2002; 20: 29-37
13. Lortholary A, Maillard P, Delva R, et al. Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study. Eur J Cancer 2000; 36: 1773-80
14. Di Leo A, Crown J, Nogaret JM, et al. A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer. Ann Oncol 2000; 11: 169-75
15. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162-70
16. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253-9
17. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163-9
18. Stebbing JJ, Gaya A. The evidence-based use of induction chemotherapy in breast cancer. Breast Cancer 2001; 8: 23-37
19. Honkoop AH, Luykx-de Bakker SA, Hoekman K, et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist 1999; 4: 106-11
20. Morrell LE, Lee YJ, Hurley J, et al. A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer 1998; 82: 503-11
21. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-9
22. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-66